ArticleTranslational oncology2019
Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent
Article in Translational oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- First-in-Human, Open-label, Single-Arm Phase I Study of [211At] meta-Astatobenzylguanidine in Patients with Pheochromocytoma or Paraganglioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Acute radiotoxicity studies and safety assessment ofScientific reports · 2025Article
- Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2025Review
- Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Theranostic Application of Radiohalogens in Nuclear Medicine.Nuclear medicine and molecular imaging · 2025Review
- Extended single-dose toxicity study of [Annals of nuclear medicine · 2025Article
- Enhancing the Stability ofACS medicinal chemistry letters · 2025Article
- Establishment and activity of the planning and acting network for low dose radiation research in Japan (PLANET): 2016-2023.Journal of radiation research · 2024Article
- Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient.The Journal of clinical endocrinology and metabolism · 2024Review
- Recent advances in the development ofAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Review
- Article
- Therapeutic efficacy ofChemical science · 2023Article
- The current status of prostate cancer treatment and PSMA theranostics.Therapeutic advances in medical oncology · 2023Review
- Astatine-211 based radionuclide therapy: Current clinical trial landscape.Frontiers in medicine · 2022Review
- Enhancing the Therapeutic Effect of 2-Cancers · 2021Article
- Utility ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Human dosimetry of freeEJNMMI physics · 2020Article
- Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.Cancer biotherapy & radiopharmaceuticals · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The α-emitter
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.